Inge Leimer

Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT® Trial

David Halpin, Marc Decramer, Bartolomé R. Celli et al. · Lung · 2011 · 86 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

Lucas Goossens, Inge Leimer, Norbert Metzdorf et al. · BMC Pulmonary Medicine · 2014 · 68 citations · Full text

Medicine, Chronic Disease Control, Clinical Classification Systems +16

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial

Donald P. Tashkin, Inge Leimer, Norbert Metzdorf et al. · Respiratory Research · 2015 · 49 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Evaluation of withdrawal of maintenance tiotropium in COPD

Antonio Anzueto, Dick D. Briggs, Inge Leimer et al. · Respiratory Medicine · 2009 · 22 citations

Medicine, Internal Medicine, Pharmacotherapy +10

Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease

Kathryn Rice, Inge Leimer, Steven Kesten et al. · Translational research · 2008 · 12 citations

Medicine, Clinical Sciences, Pharmacotherapy +14